From: Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
Subgroup | Control | NAFL | NASH | CHB without NASH | CHB with NASH |
---|---|---|---|---|---|
n | 23 | 12 | 30 | 25 | 14 |
Age | 39.91 ± 1.19 | 42.33 ± 3.57 | 38.20 ± 2.66 | 36.76 ± 2.59 | 39.00 ± 3.75 |
Male (%) | 14 (60.87%) | 8 (66.67%) | 18 (60.00%) | 16 (64.00%) | 9 (64.29%) |
Waistline | 80.96 ± 1.32 | 89.17 ± 1.19** | 92.34 ± 1.43** | 80.38 ± 3.28 | 90.00 ± 1.68** |
BMI | 23.80 ± 0.52 | 26.74 ± 0.85** | 27.73 ± 0.61** | 22.61 ± 0.64 | 26.25 ± 0.53** |
TB | 15.63 ± 0.79 | 13.48 ± 1.46 | 19.06 ± 3.32 | 25.30 ± 5.00 | 12.98 ± 0.85 |
DB | 2.53 ± 0.19 | 4.86 ± 0.69** | 9.43 ± 3.03* | 11.15 ± 3.63* | 3.97 ± 0.40** |
ALP | 69.30 ± 3.87 | 78.98 ± 9.89 | 95.38 ± 7.60** | 84.73 ± 8.66 | 96.01 ± 15.22* |
γ-GT | 25.47 ± 4.51 | 31.76 ± 4.22 | 157.26 ± 56.40* | 82.35 ± 20.69* | 46.39 ± 9.02 |
ALT | 24.17 ± 2.23 | 43.94 ± 5.70** | 99.55 ± 11.87** | 113.91 ± 30.18** | 59.13 ± 9.79** |
AST | 21.17 ± 0.93 | 24.13 ± 1.54 | 60.32 ± 6.20** | 60.93 ± 12.75** | 41.73 ± 7.23** |
TC | 4.60 ± 0.18 | 4.38 ± 0.26 | 4.84 ± 0.19 | 3.75 ± 0.17** | 5.43 ± 0.30* |
TG | 1.37 ± 0.16 | 1.51 ± 0.24 | 2.05 ± 0.22* | 1.25 ± 0.15 | 2.70 ± 0.83* |
HDL | 1.25 ± 0.04 | 1.30 ± 0.07 | 1.17 ± 0.06 | 1.12 ± 0.06 | 1.31 ± 0.08 |
LDL | 2.83 ± 0.15 | 2.78 ± 0.09 | 2.89 ± 0.13 | 2.32 ± 0.12* | 2.93 ± 0.22 |
FPG | 5.00 ± 0.14 | 6.02 ± 0.57* | 5.67 ± 0.30 | 4.83 ± 0.21 | 6.31 ± 0.84 |
Stiffness | 4.35 ± 0.20 | 6.68 ± 0.97* | 12.20 ± 2.50** | 10.13 ± 1.44** | 7.64 ± 0.93** |
CAP | 222.83 ± 7.98 | 280.42 ± 10.56** | 314.97 ± 9.27** | 241.43 ± 12.84 | 274.93 ± 12.38** |